Andy Mears – Chief Executive
Andy joined Deltex Medical in 1989 as an Electronics Engineer. Throughout his career with Deltex Medical, he has held a number of roles, including Production Manager and Operations Director. Andy was appointed as Group Sales Director in 2010, Managing Director 2015 and Chief Executive in 2018.
Natalie Wettler – Finance Director
Natalie commenced her Deltex Medical career in 2011 and has held a number of senior roles in the Group’s finance department between 2011 and 2016. Natalie re-joined the Group in January 2020 as Group Financial Controller and was appointed Group Finance Director in May 2021.She has a Bachelor of Science Degree in Cognitive Science from the University of Sheffield and qualified as a Chartered Accountant with Grant Thornton in the UK and continued her Grant Thornton career in New Zealand. Natalie’s experience in the medical sector also includes head of Finance for Peak Primary Limited in New Zealand in the Primary Healthcare sector.
Nigel Keen – Chairman
Nigel has been involved with Deltex Medical since 1988 and has been Chairman since 1996. He is also Chairman of the following companies: Oxford Academic Health Science Network, established by the National Health Service in England to align the interests of patients in its region with academia, industry and the healthcare system; and MedAccess Trust, a charity established to support MedAccess Guarantee Limited, a UK-based social finance company with the pioneering mission to make global healthcare markets work for everyone. His career has encompassed venture capital, industry and banking. He has a degree in engineering from Cambridge University and is a Fellow of the Institute of Engineering and Technology. He has been involved in the formation and development of high technology businesses for more than thirty years. Nigel is Chairman of the Remuneration Committee.
Chris Jones joined the Board in June 2015 and brings over 30 years of experience in Fortune 500 and VC funded healthcare companies in both the UK and the USA. He is Executive Chairman of: Mologic Ltd, Global Access Health Ltd, and non-executive Director of MediSieve Ltd, Causeway Therapeutics Ltd, Carbometrics Ltd and Health Enterprise East Ltd. Chris is a US national who came to the UK in 2008 to become CEO of GlySure. Prior to joining GlySure he was CEO of Tensys Medical developing and commercialising a novel continuous, non-invasive blood pressure monitor resulting in the sale of the company in 2008. Chris also spent nine years with Nellcor Inc, a division of Tyco Healthcare, most recently as VP of Marketing responsible for the $700M WW pulse oximetry and critical care businesses. He has a Bachelor of Science Degree in Molecular Biophysics and Biochemistry from Yale University.
Ben joined the Board in December 2023 and is Chairman of the Audit Committee. He has more than 15 years’ experience commercialising Software-as-a-Service (“SaaS”) platforms for start-ups and established businesses. He is currently Director of Platform Licensing at Kraken Technologies, which forms part of Octopus Energy Group. Ben was previously Chief Commercial Officer at DPR Limited and held senior commercial and finance positions at Fiserv Inc (EMEA) and MoPowered Group plc. He worked in structured finance for RBS (Global Banking Markets) after completing his MBA from Oxford University. Ben started his career working for PwC where he qualified as a Chartered Accountant, working in the UK and the Americas.